Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
TGFBR2 encodes a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. Additionally we are shipping TGFBR2 Proteins (27) and TGFBR2 Kits (15) and many more products for this protein.
Showing 10 out of 164 products:
Human Polyclonal TGFBR2 Primary Antibody for EIA, IF - ABIN955177
Inamoto, Kwartler, Lafont, Liang, Fadulu, Duraisamy, Willing, Estrera, Safi, Hannibal, Carey, Wiktorowicz, Tan, Feng, Pannu, Milewicz: TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections. in Cardiovascular research 2010
Show all 4 references for ABIN955177
Human Polyclonal TGFBR2 Primary Antibody for ELISA, WB - ABIN520882
Cook, Choudhuri, Degraff, Gamson, Mitchell: Halofuginone enhances the radiation sensitivity of human tumor cell lines. in Cancer letters 2010
Mouse (Murine) Polyclonal TGFBR2 Primary Antibody for IF, IHC (p) - ABIN655799
Liang, Li, Zhang, Cui, Quan, Yang: The anti-fibrotic effects of microRNA-153 by targeting TGFBR-2 in pulmonary fibrosis. in Experimental and molecular pathology 2015
Cow (Bovine) Polyclonal TGFBR2 Primary Antibody for WB - ABIN2781999
Song, Krebs, Danielpour: Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression. Mediation by stabilization of TGF-beta receptor type II. in The Journal of biological chemistry 2006
Expression of microRNA miR (show MYLIP Antibodies)-155 was significantly upregulated in the oropharyngeal mucosa during chronic SIV infection and was coincident with downregulation of TGFbeta (show TGFB1 Antibodies) receptor 2 (TGFbeta (show TGFB1 Antibodies)-R2) and SMAD5 (show SMAD5 Antibodies).
Epithelial TGFbeta (show TGFB1 Antibodies) signaling via TGFBR2 does not contribute to the development of liver fibrosis or formation of hepatocellular carcinomas in mice, but restricts cholangiocyte proliferation to prevent cholangiocarcinoma development.
The removal of Tgfbr2 and treatment with losartan both delayed the progression of articular cartilage degeneration induced by medial meniscus (DMM (show COL2A1 Antibodies)) compared with control littermates.
Data (including data from studies in transgenic mice) suggest intraislet pancreatic duct cells are capable of giving rise to insulin (show INS Antibodies)-secreting beta-cells; Tgfbr2/transforming growth factor-beta type II receptor appears to be involved in this process.
Elimination of TGF-betaIIR is not sufficient to completely prevent liver fibrosis. TGF-beta (show TGFB1 Antibodies)-independent mechanism of type I collagen production and suggest connective tissue growth factor (show CTGF Antibodies) as its potent mediator.
Overexpression of TGFbeta1 (show TGFB1 Antibodies) promotes pulmonary inflammation, apoptosis and mortality via TGFbetaR2 in the developing mouse lung.
Loss of smooth muscle cells Tgfbr2 disrupts TGF-beta (show TGFB1 Antibodies) signaling, acutely alters SMC (show DYM Antibodies) gene expression, and rapidly results in severe and durable aortopathy.
Increased Tgfbr2 expression is associated with pulmonary fibrosis.
High TGFBR2 expression is associated with pancreatic carcinoma.
Suggest that miR (show MLXIP Antibodies)-370 acting via TbetaRII might play a potential role in hepatic IR injury, and inhibition of miR (show MLXIP Antibodies)-370 efficiently attenuated the damage to the liver.
skeletal phenotype of mice carrying a mutation in the TGF-beta (show TGFB1 Antibodies) type 2 receptor associated with severe Loeys-Dietz syndrome in humans: Cortical bone showed significantly reduced tissue area, bone area, and cortical thickness with increased eccentricity
TGFBR2 signaling can affect Notch1 (show NOTCH1 Antibodies) glycosylation via regulation of glycosyltransferase (show GTDC2 Antibodies) LFNG (show LFNG Antibodies) expression and provide a first mechanistic example for altered glycosylation in microsatellite instability colorectal tumor cells.
CD44 (show CD44 Antibodies) and TGFBR2 are the functional targets of miR (show MLXIP Antibodies)-373, which are responsible for the tumor suppressive functions of miR (show MLXIP Antibodies)-373
Polymorphism of TGFBR2 is associated with coronary artery disease.
Exogenous expression of miR (show MLXIP Antibodies)-142-5p inhibitor resulted in a significant reduction of viral titer indicating proviral role of miR (show MLXIP Antibodies)-142-5p. Functional studies of hsa (show CD24 Antibodies)-miR (show MLXIP Antibodies)-142-5p identified its role in transforming growth factor beta (TGFbeta (show TGFB1 Antibodies)) signalling as TGFbeta (show TGFB1 Antibodies) receptor 2 and SMAD3 (show SMAD3 Antibodies) were degraded during both hsa (show CD24 Antibodies)-miR (show MLXIP Antibodies)-142-5p overexpression and rotavirus infection.
Results found TGFBR2 to be significantly related to the regulated phosphoproteome in glioblastoma as a result of integrative upstream kinase/ regulator analyses and experimentally validated as a novel regulator of glioblastoma stem cells.
Reduced expression of TGF-beta type II receptor and extracellular matrix components in response to reduced fibroblast size/mechanical force was fully reversed by restoring size/mechanical force
results suggested that high CDKN1A/p21 (show CDKN1A Antibodies) and low TGFBR2 expression was closely correlated with adverse pathological parameters and poor prognosis in breast cancer.
This work details a novel mechanism by which cellular tension regulates TGFbeta (show TGFB1 Antibodies) receptor organization, multimerization, and function.
Findings suggest that the upregulation of miR (show MLXIP Antibodies)-590-5p promotes cellular malignant behavior via the target gene TGFbetaRII in vulvar squamous cell carcinoma.
This paper highlights that targeting the BMP and TGFbeta (show TGFB1 Antibodies) type I and type II receptors causes a downregulation of XIAP (show XIAP Antibodies), TAK1 (show MAP3K7 Antibodies), and Id1 (show ID1 Antibodies) leading to cell death of lung cancer cells.
These results indicate that high plasma cholesterol levels may contribute to the pathogenesis of certain diseases (e.g., atherosclerosis) by suppressing TGF-beta (show TGFB1 Antibodies) responsiveness.
This gene encodes a member of the Ser/Thr protein kinase family and the TGFB receptor subfamily. The encoded protein is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation. Mutations in this gene have been associated with Marfan Syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. Alternatively spliced transcript variants encoding different isoforms have been characterized.
transforming growth factor, beta receptor II (70/80kDa)
, transforming growth factor beta type II receptor
, transforming growth factor, beta receptor II
, transforming growth factor beta receptor 2
, TGF-beta receptor type-2
, TGF beta receptor type II
, TGF-beta receptor type-2-like
, TGF-beta receptor II
, TGF-beta receptor type II
, TGF-beta type II receptor
, transforming growth factor-beta receptor type II
, transforming growth factor beta receptor type II
, transforming growth factor beta, receptor 2
, transforming growth factor, beta receptor 2
, transforming growth factor, beta receptor IIT
, transforming growth factor-b type II receptor
, transforming growth factor-beta type II receptor
, TGF-beta receptor type IIB
, transforming growth factor beta receptor type IIC